Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications

The remarkable clinical success of Fc-fusion proteins has driven intense investigation for even more potent replacements. Using quality-by-design (QbD) approaches, we generated hexameric-Fc (hexa-Fc), a ~20 nm oligomeric Fc-based scaffold that we here show binds low-affinity inhibitory receptors (Fc...

Descripción completa

Detalles Bibliográficos
Autores principales: Czajkowsky, Daniel M., Andersen, Jan Terje, Fuchs, Anja, Wilson, Timothy J., Mekhaiel, David, Colonna, Marco, He, Jianfeng, Shao, Zhifeng, Mitchell, Daniel A., Wu, Gang, Dell, Anne, Haslam, Stuart, Lloyd, Katy A., Moore, Shona C., Sandlie, Inger, Blundell, Patricia A., Pleass, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224519/
https://www.ncbi.nlm.nih.gov/pubmed/25912958
http://dx.doi.org/10.1038/srep09526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224519/
https://www.ncbi.nlm.nih.gov/pubmed/25912958
http://dx.doi.org/10.1038/srep09526

Ejemplares similares